ONCT vs. MREO

Last updated Jun 4, 2026

ONCT (Oncternal Therapeutics, Inc.) and MREO (Mereo BioPharma Group plc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.07 correlation, their price movements are largely independent.

Performance

ONCT vs. MREO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Oncternal Therapeutics, Inc. (ONCT) and Mereo BioPharma Group plc (MREO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

ONCT

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

MREO

• 1D: -1.53%
• 1M: 16.41%
• YTD: -19.80%
• 6M: -82.95%
• 1Y: -87.39%
• 3Y*: -31.94%
• 5Y*: -37.84%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ONCT vs. MREO - Yearly Performance Comparison

	2026 (YTD)
ONCT Oncternal Therapeutics, Inc.	0.00%
MREO Mereo BioPharma Group plc	-21.27%

Correlation

The correlation between ONCT and MREO is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (All Time) Calculated using the full available price history since Feb 9, 2026	0.07

Fundamentals

Total Revenue (TTM) ONCT : $1.67M MREO : $500.00K
Gross Profit (TTM) ONCT : -$16.96M MREO : $366.00K
EBITDA (TTM) ONCT : -$17.87M MREO : -$39.61M

Return for Risk

ONCT vs. MREO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MREO

MREO Risk / Return Rank: 14
MREO Sharpe Ratio Rank: 13
MREO Sortino Ratio Rank: 24
MREO Omega Ratio Rank: 20
MREO Calmar Ratio Rank: 4
MREO Martin Ratio Rank: 8

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ONCT vs. MREO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Oncternal Therapeutics, Inc. (ONCT) and Mereo BioPharma Group plc (MREO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	ONCT	MREO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.65	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.38	—
Sharpe Ratio (All Time) Calculated using the full available price history	1.68	-0.30	+1.98

Drawdowns

ONCT vs. MREO - Drawdown Comparison

The maximum ONCT drawdown since its inception was 0.00%, smaller than the maximum MREO drawdown of -96.35%. Use the drawdown chart below to compare losses from any high point for ONCT and MREO.

Drawdown Indicators

	ONCT	MREO	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-96.35%	+96.35%
Max Drawdown (1Y) Largest decline over 1 year	—	-91.93%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-95.13%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-95.13%	—
Current Drawdown Current decline from peak	0.00%	-94.86%	+94.86%
Average Drawdown Average peak-to-trough decline	0.00%	-65.90%	+65.90%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	62.66%	—

Volatility

Volatility by Period

	ONCT	MREO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	36.10%	—
Volatility (6M) Calculated over the trailing 6-month period	—	224.43%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	134.18%	-134.18%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	100.56%	-100.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	113.66%	-113.66%

Dividends

ONCT vs. MREO - Dividend Comparison

Neither ONCT nor MREO has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ONCT and MREO in my portfolio?

ONCT and MREO have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.